Contact
searchSearch
HMP Global
Login

Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Specialty Channel
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
Quiz
Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
News
Dose-Reduced Chemotherapy Expands Treatment Options for Frail Patients with Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology

News

News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Dose-Reduced Chemotherapy Expands Treatment Options for Frail Patients with Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology

Interactive Features

Quiz
Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Oxaliplatin-Based Chemotherapy and Targeted Agents for Metastatic Colorectal Cancer
11/24/2025
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors...
11/24/2025
Oncology
Quiz
Adding Bevacizumab to Trifluridine and Tipiracil for Previously Treated Patients With Metastatic Colorectal Cancer
09/30/2025
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis...
09/30/2025
Oncology
Quiz
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
08/05/2025
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to...
08/05/2025
Oncology
Quiz
Sotorasib Plus Panitumumab and FOLFIRI for Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
07/23/2025
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to...
07/23/2025
Oncology

Recent News

News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Encorafenib-Cetuximab Plus Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer
02/24/2026
Gina Tomaine
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA granted traditional approval to frontline encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected...
On February 24, 2026, the FDA...
02/24/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
News
Eribulin Demonstrates Limited Efficacy in BRAF V600E-Mutated Metastatic Colorectal Cancer
11/04/2025
Stephanie Holland
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY...
11/04/2025
Oncology
News
Panitumumab Plus Regorafenib Treatment Sequence Did Not Significantly Impact Survival in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
10/29/2025
Stephanie Holland
Final results from the phase 2 PARERE study demonstrate that the treatment sequence of panitumumab plus regorafenib did not significantly impact overall survival results among patients with RAS and BRAF wild-type metastatic colorectal cancer.
Final results from the phase 2 PARERE study demonstrate that the treatment sequence of panitumumab plus regorafenib did not significantly impact overall survival results among patients with RAS and BRAF wild-type metastatic colorectal cancer.
Final results from the phase 2...
10/29/2025
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology
News
Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
09/15/2026
Emily Estrada
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...
Topline results from the phase 3...
09/15/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use